Sanofi’s SAR446268 Gene Therapy Study: A Potential Game-Changer for Myotonic Dystrophy

Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.

Sanofi is currently conducting a Phase 1/Phase 2 clinical study titled ‘A Phase 1/Phase 2 Open-label Single Arm Study With Dose Escalation (Part A), and Dose Expansion (Part B) Parts to Evaluate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants 10 to 50 Years Old With Non-congenital Myotonic Dystrophy Type 1.’ The study aims to assess the safety and efficacy of SAR446268, a gene therapy designed to reduce dystrophia myotonica protein kinase (DMPK) mRNA levels and enhance neuromuscular function in patients with non-congenital myotonic dystrophy type 1 (DM1).

The intervention being tested is SAR446268, a biological solution administered via intravenous infusion. It is intended to provide a novel treatment option for DM1 by targeting the underlying genetic cause of the disease.

This interventional study is open-label, single-arm, and involves dose escalation and expansion phases. Participants receive a single dose of SAR446268, with the primary purpose being treatment. There is no masking involved in this study.

The study began on July 23, 2025, with the last update submitted on August 7, 2025. These dates are crucial as they mark the commencement of participant recruitment and the latest information available about the study’s progress.

The market implications of this study are significant for Sanofi, as successful results could enhance its position in the gene therapy sector and positively influence its stock performance. Investors will be keenly watching for updates, especially given the competitive landscape in genetic therapies for neuromuscular disorders.

The study is ongoing, and further details are available on the ClinicalTrials portal.